Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

BACKGROUND. Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. MATERIALS AND METHODS. This prospective, multi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Capdevila, Jaume, Teulé, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, García‐Carbonero, Rocío, Dotor, Emma, Matos, Ignacio, Custodio, Ana, Casanovas, Oriol, Salazar, Ramon
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2018
Teme:
Endocrinology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324631/
https://ncbi.nlm.nih.gov/pubmed/29794066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0622
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki